Alpha-Lipoic Acid

Alpha-lipoic acid is unusual among the supplements on this site: in Germany it is not a supplement at all. Marketed as thioctic acid, it is a registered medicine for diabetic peripheral neuropathy, and the standard dose written into that practice — 600 mg a day — is the same number the trials keep landing on. Treatment is often begun intravenously for a short course and then continued orally, to relieve the burning, stabbing, tingling and numbness of damaged nerves in the feet.

This page is about what alpha-lipoic acid does to blood sugar and metabolism, and how to dose it. The compound itself — its biochemistry, its role in mitochondrial energy production, heavy-metal chelation, R- versus racemic forms — is covered on the alpha-lipoic acid compound profile, and is not repeated here.

Table of Contents

  1. A Short Working Window
  2. Lower Blood Sugar
  3. Reduction in Insulin
  4. Weight Loss
  5. Leptin and Adiponectin
  6. Improvements in Blood Flow
  7. Regenerating Vitamin C, Vitamin E and CoQ10
  8. You Cannot Eat Your Way to the Dose
  9. Dosing: 600, 1,200 and 2,400 mg
  10. The German Protocol
  11. Taking ALA With Biotin
  12. Cautions
  13. Key Research Papers
  14. Connections
  15. Featured Videos

A Short Working Window

The single most practical fact about alpha-lipoic acid is that it does not stay around. It is absorbed quickly, peaks in the blood quickly, and clears quickly. Amenta and colleagues compared four 600 mg formulations head to head in healthy volunteers — including Thioctacid 600 mg HR, the registered German preparation — and found that total exposure was similar across all four, while the peak concentration and the time taken to reach it differed substantially between them. A fast formulation gets higher, sooner. None of them produces a plateau that lasts through the day.

That short window is the organising fact behind everything below, and it explains three things at once:

  1. Why the dose is split or timed rather than taken casually. A once-daily tablet covers part of a day, not all of it.
  2. Why the German protocol front-loads with an intravenous course. Infusion sidesteps absorption entirely and puts the compound where it is wanted at a concentration oral dosing reaches only briefly.
  3. Why an empty stomach is usually advised. Food lowers absorption, and with a compound this short-acting, a blunted peak is most of the dose wasted.

One caution about a number that circulates widely. Alpha-lipoic acid is often said to "last about five hours in the body." The published pharmacokinetic work does not report a figure like that; what it reports is rapid absorption, a short-lived peak, and formulation-dependent differences in how high that peak goes. Shay and colleagues at the Linus Pauling Institute also note that the meaningful biological effects occur at low micromolar concentrations, so the useful window is not simply the window in which the compound is detectable. The practical conclusion people draw from "five hours" — that ALA is short-acting and needs deliberate timing rather than 24-hour coverage — is right. The specific number is not something the literature supports.

Back to Table of Contents

Lower Blood Sugar

The best summary of the glucose evidence is Akbari and colleagues' 2018 meta-analysis in Metabolism, which pooled 24 randomised controlled trials of alpha-lipoic acid in people with metabolic disease. Supplementation significantly reduced every glycemic measure examined:

The same analysis found reductions in triglycerides (SMD −0.58), total cholesterol (−0.64) and LDL cholesterol (−0.44), with no adverse effect on HDL.

Two things are worth holding onto. First, these are standardised mean differences, not milligrams per decilitre — they express effect size, and converting them into an expected drop in your own fasting glucose is not something the pooled data supports. Second, the trials were in people with metabolic disease. Nothing here says a person with normal glucose will see their numbers move, and the reasonable expectation in that case is that they will not. If you want to know what it does for you specifically, that is what glucose monitoring is for.

Back to Table of Contents

Reduction in Insulin

The insulin and HOMA-IR results above are, mechanistically, the more interesting half of the glucose finding. Fasting insulin falling alongside fasting glucose is the signature of improved insulin sensitivity rather than of a drug pushing glucose down by force: if the pancreas is having to shout less loudly to achieve the same or better glucose control, the tissue is listening better.

That distinction matters because chronically elevated insulin does damage of its own, independent of glucose — it drives ovarian androgen production, VLDL secretion, renal sodium retention, and is the upstream abnormality present for a decade or two before Type 2 diabetes is ever diagnosed. The insulin resistance page covers that mechanism in full, along with why fasting insulin is the test that reveals it years before glucose moves.

Shay's review describes the plausible cellular route: alpha-lipoic acid improves glucose handling, increases endothelial nitric oxide synthase activity, activates the Nrf2 detoxification pathway, and represses NF-κB signalling — effects achieved at low micromolar concentrations, which is to say at concentrations oral dosing can actually reach.

Back to Table of Contents

Weight Loss

Kucukgoncu and colleagues at Yale pooled 10 randomised, double-blind, placebo-controlled trials in Obesity Reviews and found that alpha-lipoic acid produced 1.27 kg more weight loss than placebo (95% CI 0.25 to 2.29) and a BMI difference of −0.43 kg/m² (95% CI −0.82 to −0.03).

That is a real, statistically significant effect and it is a small one. The authors describe it as "small, yet significant short-term weight loss." About 1.3 kg is roughly three pounds — worth having, not worth reorganising a plan around, and not in the same category as the interventions on the exercise and meal timing page or the GLP-1 receptor agonists.

One finding from that paper deserves more attention than it usually gets: meta-regression showed no significant effect of ALA dose on either weight or BMI change. Taking more did not produce more weight loss. That is a direct, empirical argument against dose escalation, and it comes up again below.

Back to Table of Contents

Leptin and Adiponectin

Leptin is the satiety hormone secreted by fat tissue; adiponectin is the insulin-sensitising hormone from the same tissue that, unusually, falls as fat mass rises. Haghighatdoost and colleagues pooled seven randomised trials in the European Journal of Clinical Pharmacology and found alpha-lipoic acid significantly lowered serum leptin (weighted mean difference −3.63; 95% CI −5.63 to −1.64) and significantly raised adiponectin (WMD +1.98; 95% CI from 0.92).

Both directions are the favourable ones in metabolic terms. But heterogeneity between the studies was high — I² = 80.7% for leptin — meaning the trials disagreed with each other considerably, and a pooled average across disagreeing studies is a weaker thing than the same average across consistent ones. Treat this as a real signal with a wide margin around it rather than a settled number.

A falling leptin level is also easy to misread. In obesity, leptin is typically high and the problem is resistance to it, not deficiency — so a fall accompanying weight loss is generally the expected direction of travel, not independent evidence that appetite signalling has been repaired.

Back to Table of Contents

Improvements in Blood Flow

Heinisch and colleagues at the Medical University of Vienna randomised 30 people with Type 2 diabetes to 600 mg of alpha-lipoic acid or placebo for 21 days and measured forearm blood flow responses directly. Alpha-lipoic acid improved endothelium-dependent vasodilatation — the blood vessel's own response to acetylcholine — while leaving the endothelium-independent response to glycerol trinitrate unchanged. That pattern is the informative one: it locates the improvement in the vessel lining itself rather than in the smooth muscle.

Two caveats, both from the authors. The treatment was intravenous, not oral, so this trial does not establish that a 600 mg tablet does the same thing. And as they put it, whether this "salutary action translates into vascular risk reduction remains to be established" — a measurable improvement in vessel reactivity over three weeks is not the same as fewer heart attacks over years.

Back to Table of Contents

Regenerating Vitamin C, Vitamin E and CoQ10

This is the property that made alpha-lipoic acid famous, and it is genuinely unusual. Most antioxidants are consumed when they do their job: the molecule neutralises a radical and is itself oxidised. Alpha-lipoic acid and its reduced partner dihydrolipoic acid form a redox couple that can hand electrons back to other antioxidants, returning them to their active form. Packer's 1995 paper in Free Radical Biology and Medicine laid out the case for treating it as a biological antioxidant on those grounds, and the description of it as a network hub that recycles vitamin C, vitamin E and coenzyme Q10 comes from this line of work.

It is also the claim to hold most loosely. Shay's review is careful about what has actually been demonstrated where: alpha-lipoic acid scavenges free radicals, chelates metals, and restores intracellular glutathione levels that otherwise decline with age — glutathione being the effect with the most direct support. Much of the wider recycling network is characterised in cell and animal models rather than by measuring vitamin E status in supplemented humans. The same review makes the sharper point that the benefits "extend beyond the strict definition of an antioxidant" — the Nrf2 and NF-κB signalling effects are probably doing more of the work than radical scavenging is.

So: a real and well-described mechanism, and not a reason on its own to expect a clinical result. See the antioxidants section for how this fits the wider network.

Back to Table of Contents

You Cannot Eat Your Way to the Dose

Alpha-lipoic acid does occur in food — spinach, broccoli, tomatoes, and organ meats such as liver, heart and kidney are the usual sources. In food it is almost entirely bound to lysine residues in proteins, as lipoyllysine, and it is present in microgram quantities.

The therapeutic dose is 600 milligrams. The gap between what a good diet supplies and what the trials used is roughly three orders of magnitude, and it cannot be closed by eating more vegetables. Anyone taking alpha-lipoic acid for the effects on this page is taking a supplement or a medicine, and there is no food-first version of this particular intervention.

That is worth stating plainly, because it is the opposite of the situation with most things on this site. It is also why the free, unbound supplemental form behaves differently from the protein-bound dietary form: they are not interchangeable at any realistic intake.

Back to Table of Contents

Dosing: 600, 1,200 and 2,400 mg

Alpha-lipoic acid is typically sold in 600 mg capsules, which makes the practical ladder one, two or four pills a day. The trial evidence has something unusually specific to say about which rung to stand on, and it is not the top one.

The SYDNEY 2 trial randomised 181 people with diabetic distal symmetric polyneuropathy to 600 mg, 1,200 mg or 1,800 mg of oral alpha-lipoic acid once daily, or placebo, for five weeks. The Total Symptom Score fell by:

  1. 600 mg — 4.9 points, a 51% reduction; 62% of patients were responders.
  2. 1,200 mg — 4.5 points, 48%; 50% responders.
  3. 1,800 mg — 4.7 points, 52%; 56% responders.
  4. Placebo — 2.9 points, 32%; 26% responders.

All three doses beat placebo. None of them beat each other. Three times the dose produced no additional symptom relief — and the safety analysis showed a dose-dependent increase in nausea, vomiting and vertigo. The authors' conclusion is unusually direct for a clinical paper: an oral dose of 600 mg once daily appears to provide the optimum risk-to-benefit ratio.

Two further points about the higher rungs:

Practical shape, then: 600 mg is the dose the evidence supports. Higher doses exist, have been tested up to 1,800 mg, and are reasonable to discuss with a prescriber for neuropathy that has not responded — but they should be understood as trading tolerability for no measured gain, not as trying harder.

Back to Table of Contents

The German Protocol

In Germany alpha-lipoic acid occupies a category it holds almost nowhere else. As thioctic acid it is a licensed medicine for diabetic peripheral neuropathy rather than a supplement, prescribed at 600 mg daily, and the pharmacokinetic literature refers to Thioctacid 600 mg HR as the registered preparation available there. Much of the trial evidence in this field is German in origin: the ALADIN series and SYDNEY 2 were run out of the German Diabetes Center in Düsseldorf under Dan Ziegler.

The characteristic protocol is a short intravenous course followed by oral maintenance. The rationale follows directly from the pharmacokinetics in the first section: infusion bypasses the absorption bottleneck and achieves concentrations oral dosing reaches only fleetingly, which matters most at the start of treatment when symptoms are worst. Once symptoms are controlled, oral dosing maintains it.

Worth being clear about the indication. The German licence is for neuropathy symptoms — the pain, burning, tingling and numbness of damaged nerves — not for glucose control. The metabolic effects in the sections above are real and measured, but they are not what the medicine is registered to treat, and a reader who takes ALA expecting it to manage their diabetes rather than their nerve pain has the emphasis backwards.

Back to Table of Contents

Taking ALA With Biotin

Combination products pairing alpha-lipoic acid with biotin are widely sold, and the rationale given is a genuine piece of biochemistry: lipoic acid and biotin are both substrates of the sodium-dependent multivitamin transporter (SMVT), the intestinal and cellular carrier that also handles pantothenate. Because they compete for the same carrier, the concern is that sustained high-dose lipoic acid could interfere with biotin uptake, and adding biotin is offered as insurance against that.

The transporter is shared — that much is established. What we could not find is human evidence that alpha-lipoic acid supplementation actually produces clinically meaningful biotin deficiency. So the honest position is: the mechanism is real, the consequence is unproven, and a combination product is a low-risk hedge rather than a correction of a documented problem. Biotin is inexpensive, water-soluble and well tolerated, so there is little argument against taking it — but there is also no need to believe you are treating a deficiency.

One practical warning that has nothing to do with ALA and everything to do with biotin: supplemental biotin interferes with many laboratory immunoassays, including thyroid panels and cardiac troponin, and can produce results that look like real disease. Tell whoever orders your blood work that you take it, and stop it before testing if they advise. See vitamin B7 and biotin and blood sugar.

Back to Table of Contents

Cautions

  1. It lowers blood glucose, and so does your medication. The effects add. If you take insulin or a sulfonylurea, adding alpha-lipoic acid can push you into hypoglycemia; dose changes belong with the prescriber. See hypoglycemia awareness and prevention.
  2. Nausea, vomiting and vertigo rise with the dose. This is the documented safety finding from SYDNEY 2, and it is the main reason the 600 mg rung is the recommended one.
  3. Thiamine status matters in heavy drinkers. Alpha-lipoic acid is often given alongside thiamine in that setting rather than instead of it; see vitamin B1.
  4. It chelates metals. That is one of its described properties, and it means the interaction surface with mineral supplements and with any prescribed chelation therapy is real. Space doses apart and mention it.
  5. Neuropathy needs a diagnosis, not a supplement. Burning or numb feet have several causes, some urgent. The German protocol exists inside a clinical assessment; buying capsules does not reproduce that.
  6. Pregnancy and breastfeeding are not studied at these doses.

Back to Table of Contents

Key Research Papers

Every DOI below was checked against Crossref and the abstract read for support before it was listed.

  1. Ziegler D, Ametov A, Barinov A, et al. Oral Treatment With α-Lipoic Acid Improves Symptomatic Diabetic Polyneuropathy: the SYDNEY 2 trial. Diabetes Care, 2006;29(11):2365–2370. The 600 / 1,200 / 1,800 mg comparison, and the source of the optimum-risk-to-benefit conclusion.
  2. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicentre randomized controlled trial (ALADIN III). Diabetes Care, 1999;22(8):1296–1301.
  3. Akbari M, Ostadmohammadi V, Lankarani KB, et al. The effects of alpha-lipoic acid supplementation on glucose control and lipid profiles among patients with metabolic diseases: A systematic review and meta-analysis. Metabolism, 2018;87:56–69. Twenty-four randomised trials; the fasting glucose, insulin, HOMA-IR and HbA1c figures quoted above.
  4. Kucukgoncu S, Zhou E, Lucas KB, Tek C. Alpha-lipoic acid (ALA) as a supplementation for weight loss: results from a meta-analysis of randomized controlled trials. Obesity Reviews, 2017;18(5):594–601. The 1.27 kg figure, and the meta-regression showing dose did not matter.
  5. Haghighatdoost F, Gholami A, Hariri M. Alpha-lipoic acid effect on leptin and adiponectin concentrations: a systematic review and meta-analysis of randomized controlled trials. European Journal of Clinical Pharmacology, 2020;76(5):649–657.
  6. Heinisch BB, Francesconi M, Mittermayer F, et al. Alpha-lipoic acid improves vascular endothelial function in patients with type 2 diabetes: a placebo-controlled randomized trial. European Journal of Clinical Investigation, 2010;40(2):148–154. Intravenous, 21 days, forearm blood flow.
  7. Shay KP, Moreau RF, Smith EJ, Smith AR, Hagen TM. Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochimica et Biophysica Acta, 2009;1790(10):1149–1160. The Linus Pauling Institute review; glutathione restoration, eNOS, Nrf2 and the low-micromolar point.
  8. Packer L, Witt EH, Tritschler HJ. Alpha-lipoic acid as a biological antioxidant. Free Radical Biology and Medicine, 1995;19(2):227–250. The origin of the antioxidant-recycling framework.
  9. Amenta F, Traini E, Tomassoni D, Mignini F. Pharmacokinetics of different formulations of tioctic (alpha-lipoic) acid in healthy volunteers. Clinical and Experimental Hypertension, 2008;30(8):767–775. Four 600 mg formulations compared, including the registered German one.

Live PubMed Topic Searches

  1. ALA and diabetic neuropathy
  2. ALA and glycemic control
  3. ALA and insulin sensitivity
  4. ALA and body weight
  5. ALA, leptin and adiponectin
  6. ALA and endothelial function
  7. ALA and glutathione
  8. Thioctic acid pharmacokinetics
  9. Lipoic acid, biotin and SMVT
  10. R-ALA vs racemic bioavailability

Back to Table of Contents

Connections

Back to Table of Contents